




CONVEGNO FISiM

Firenze, CSF Montedomini

“Il Fuligno”

24-25 ottobre 2025

Eltrombopag in Hypocellular Myelodysplastic Neoplasms

Elena Crisà MD

Candiolo Cancer Institute IRCCs -FPO



Disclosures of Elena Crisà

Company name	Research support	Employee	Consultant	Stockholder	Speakers bureau	Advisory board	Other
GSK						X	
JANSSEN	X						
BMS					X		




EQoL-MDS: Platelet response

Factors **not** associated with response:

- Gender,
- MDS duration
- WHO classification
- IPSS, IPSS-R
- Cytogenetics
- Bleeding
- PLT transfusions
- **Hypoplasia**
- fibrosis

Median daily dose at response
50 mg (IQR 50-150 mg)



AML evolution and/or disease progression occurred in 17% (for both) of eltrombopag and placebo patients with no difference in survival times

